Colon Pharmaceutical (002422) 2023 Report Review: Multi-wheel Drive Steady Growth and Innovative Layout Usher in a Harvest Period
Colon Pharmaceutical (002422): Performance is in line with expectations, and the large infusion and API sector is growing steadily
Colon Pharmaceuticals (002422): Rapid performance growth focuses on pipeline clinical and commercialization promotion
Colon Pharmaceutical (002422): Excellent performance in the infusion business, innovation, transformation and acceleration of implementation
Colon Pharmaceutical (002422): Three steps drive performance growth, innovative R&D and efficient promotion
China Galaxy released a research report on April 24 stating that it gave Colon Pharmaceutical (002422.SZ) a recommended rating. The main reasons for the rating include: 1) Infusion continues to exceed expectations, demand is strong & structure is optimize
Colon Pharmaceuticals (002422): Continued strong trend in 1Q, all sectors attacked at full speed
Colon Pharmaceuticals (002422): Three-engine drive transcends Mylan
Colon Pharmaceutical (002422): The three-pronged strategy continues to implement the innovative layout and enters a harvest period
Colon Pharmaceutical (002422): Three drivers lead steady growth, large infusion leaders enter a new stage of innovation and development
Colon Pharmaceutical (002422) Company In-depth Report: Three Moves to Start a New Cycle of Evergreen Innovation in the Foundation Industry
Colon Pharmaceutical (002422): Twinning's performance exceeded expectations and cooperation with MSD is progressing steadily
Colon Pharmaceutical (002422): Core business development is steady and innovation pipelines are progressing smoothly
Colon Pharmaceutical (002422): Revenue and profit meet expectations, global innovation and transformation continue to advance
Colon Pharmaceutical (002422) Three Quarterly Report Review: Excellent performance under a high base, optimistic about Big Infusion and Twining's annual performance
Colon Pharmaceutical (002422): Performance meets expectations, focuses on pipeline clinical progress at home and abroad
Colon Pharmaceutical (002422): Three Business Sectors Reveal New Innovation Drives Long-term Growth
Colon Pharmaceutical (002422): Steady Growth in Infusion Cornerstone Business Drives Innovation and Upgrading
Colon Pharmaceutical (002422): Innovative drug clinical trials are advancing rapidly and entering the harvest period, and the three major sectors are growing steadily
Colon Pharmaceutical (002422): Large-scale infusion APIs are growing rapidly, innovative research and development is progressing smoothly
No Data